Please login to the form below

Not currently logged in
Email:
Password:

tivantinib

This page shows the latest tivantinib news and features for those working in and with pharma, biotech and healthcare.

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

trials, with recent fails including c-MET inhibitor tivantinib.

Latest news

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    These include tivantinib for liver cancer - tipped by some analysts as a $600m product despite disappointing data in lung cancer - quizartinib for leukaemia and mirogabalin for fibromyalgia.

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    It remains to be seen whether the failed study has implications for other c-MET inhibitors in clinical trials, although the class has had other notable casualties, including ArQule's tivantinib

  • Daiichi, ArQule cancer drug tivantinib flunks another trial Daiichi, ArQule cancer drug tivantinib flunks another trial

    Tivantinib is a first in-class inhibitor of MET, a receptor tyrosine kinase thought to play a role in the development of a number of human cancers. ... to proceed with further clinical development of tivantinib in this tumour type ". 14th January 2013.

  • Russian market for lung cancer drugs to hit $163m by 2015

    Kirin's tivantinib - should make their debut in or before 2015.". ... Meanwhile, Daiichi Sankyo began enrolling patients in Europe into a large, multinational phase III trial of tivantinib, its investigational small molecule inhibitor of the c-MET

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics